TRPV1 and hearing loss disorder: TRPV1 activation by cisplatin was therefore implicated in cisplatin-induced hearing loss, and indeed, reducing TRPV1 expression (by siRNA treatment) or TRPV1 activity (by capsazepine or ruthenium red) in the inner ear reduced cisplatin-induced hearing loss [142].